Our Accomplishments:
Sorrento has had a long journey from a humble beginning to a diversified biopharma discovering and developing life changing medicine.
2009
Founded
2013
Acquired Resiniferatoxin (RTX) assets via the acquisition of Sherrington Pharmaceuticals Inc.
Acquired Antibody Drug Conjugation (ADC) technologies via acquisition of Concortis Biosystems Corp.
2014
Out-licensed PD-L1 for Greater China market to Lee’s Pharm
2016
Formed ImmuneOncia JV with Yuhan Pharmaceuticals
Acquired ZTlido® via majority stake in Scilex Pharmaceuticals
Acquired Bioserv Corporation for cGMP manufacturing operations
Formed Levena Suzhou Biopharma Co. LTD for Antibody Drug Conjugation (ADC) services
2017
Acquired Oncolytic Virus platform via the acquisition of Virttu Biologics Limited
Formed Celularity with Celgene and United Therapeutics
2018
Acquired Sofusa® Lymphatic Delivery System from Kimberly-Clark
2019
Acquired Semnur Pharmaceuticals
Formed Scilex Holding to consolidate the merger of Scilex Pharma and Semnur Pharma
2020
Exclusively licensed Abivertinib from ACEA Therapeutics for all indications worldwide, excluding China
Exclusively licensed HP-LAMP diagnostic platform from Columbia University for the detection of coronaviruses and influenza viruses
Acquired SmartPharm Therapeutics
2021
Acquired ACEA Therapeutics
2022
Acquired Virexhealth
